Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

BTK Inhibitors Mushroom in Blood Cancer Field

January 20th 2017

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

Dr. James on Update of Ibrutinib for Chronic Lymphocytic Leukemia

January 18th 2017

Danelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.

Frontline Ibrutinib Benefit Sustained in Pivotal CLL Trial Update

January 17th 2017

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

Dr. von Tresckow on "Sequential Triple-T" Trial in CLL

January 14th 2017

Julia von Tresckow, MD, specialist in oncology, University of Cologne, Department of Internal Medicine, and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, discusses the CLL2-BIG trial, which explored the combination of obinutuzumab (Gazyva) and ibrutinib (Imbruvica) for induction and maintenance treatment of physically fit and unfit patients with chronic lymphocytic leukemia (CLL). Patients with high tumor burden were given bendamustine as debulking.

The Future of Treatment of B-Cell Lymphoma

January 13th 2017

DLBCL: CAR-T as Curative Treatment/Bridge to Transplant

January 13th 2017

CAR-T Therapy for DLBCL

January 13th 2017

Relapsed/Refractory DLBCL

January 13th 2017

Maintenance Therapy for DLBCL

January 13th 2017

Treating High-Grade Lymphoma

January 13th 2017

Risk-Based Therapy for DLBCL

January 13th 2017

CAR-T Cell Therapies in CLL

January 13th 2017

Ibrutinib for CLL with Deletion 17p

January 13th 2017

Managing Ibrutinib Toxicity in CLL

January 13th 2017

Sequencing Therapies for Relapsed/Refractory CLL

January 13th 2017

The Role of Maintenance Therapy in CLL

January 13th 2017

CLL Risk Stratification and Treatment Approach

January 13th 2017

Chronic Lymphocytic Leukemia; Initiating Therapy

January 13th 2017

Emerging Therapies for Follicular Lymphoma

January 13th 2017

R2-CHOP for Relapsed Follicular Lymphoma

January 13th 2017